The overexpression of GLUT-1 observed in invasive breast cancer and in carcinoma in situ lesions may present a tumor metabolic prognostic marker and also an interesting target therapy, independently of patient metabolic disorder. Here, SLC2A1 is linked to Other metabolic disease.